Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ophthalmology (15) 15
humans (14) 14
science & technology (13) 13
female (12) 12
life sciences & biomedicine (12) 12
aged (11) 11
male (11) 11
middle aged (11) 11
aged, 80 and over (8) 8
fluorescein angiography (8) 8
intravitreal injections (8) 8
tomography, optical coherence (8) 8
bevacizumab (7) 7
prospective studies (7) 7
angiogenesis inhibitors - therapeutic use (6) 6
vascular endothelial growth factor a - antagonists & inhibitors (6) 6
visual acuity - physiology (6) 6
antibodies, monoclonal, humanized (5) 5
macular degeneration (5) 5
macular edema - drug therapy (5) 5
ranibizumab (5) 5
retina - pathology (5) 5
adult (4) 4
angiogenesis inhibitors - administration & dosage (4) 4
antibodies, monoclonal - adverse effects (4) 4
antibodies, monoclonal - therapeutic use (4) 4
clinical trials (4) 4
injections (4) 4
macular edema - etiology (4) 4
retrospective studies (4) 4
visual acuity (4) 4
vitreous body (4) 4
antibodies, monoclonal - administration & dosage (3) 3
choroidal neovascularization - diagnosis (3) 3
choroidal neovascularization - drug therapy (3) 3
choroidal neovascularization - physiopathology (3) 3
diabetes (3) 3
diabetic retinopathy (3) 3
diabetic retinopathy - drug therapy (3) 3
drug therapy (3) 3
eye (3) 3
eye diseases (3) 3
follow-up studies (3) 3
genetic structures (3) 3
physiological aspects (3) 3
research (3) 3
retinal vein occlusion - complications (3) 3
treatment outcome (3) 3
vascular endothelial growth factor (3) 3
wet macular degeneration - drug therapy (3) 3
abridged index medicus (2) 2
angiogenesis inhibitors (2) 2
angiogenesis inhibitors - adverse effects (2) 2
angiogenesis inhibitors - pharmacokinetics (2) 2
animals (2) 2
anti-vegf (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
biological and medical sciences (2) 2
cohort studies (2) 2
comparative analysis (2) 2
diabetic retinopathy - complications (2) 2
enzyme-linked immunosorbent assay (2) 2
geographic atrophy - physiopathology (2) 2
macular degeneration - complications (2) 2
macular degeneration - diagnosis (2) 2
macular degeneration - drug therapy (2) 2
macular degeneration - physiopathology (2) 2
macular edema (2) 2
medical sciences (2) 2
miscellaneous (2) 2
oncology (2) 2
online first (2) 2
pharmacokinetics (2) 2
recombinant fusion proteins - pharmacokinetics (2) 2
retina (2) 2
retina - drug effects (2) 2
retina - metabolism (2) 2
vascular endothelial growth factor a - blood (2) 2
vascular endothelial growth factor a - immunology (2) 2
vitreous body - metabolism (2) 2
wet macular degeneration - diagnosis (2) 2
1506 (1) 1
acuity (1) 1
age (1) 1
age-related macular degeneration (1) 1
albinism (1) 1
alleles (1) 1
analysis (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - toxicity (1) 1
angiography (1) 1
anti-tumor necrosis factor alpha (1) 1
antibodies, monoclonal (1) 1
antibodies, monoclonal - immunology (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - pharmacokinetics (1) 1
arteries (1) 1
association (1) 1
atrophy (1) 1
avastin (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
by Avery, Robert L and Castellarin, Alessandro A and Steinle, Nathan C and Dhoot, Dilsher S and Pieramici, Dante Joseph and See, Robert and Couvillion, Stephen and Nasir, Ma'an A and Rabena, Melvin D and Le, Kha and Maia, Mauricio and Visich, Jennifer E
British journal of ophthalmology, ISSN 0007-1161, 12/2014, Volume 98, Issue 12, pp. 1636 - 1641
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Prospective Studies | Enzyme-Linked Immunosorbent Assay | Intravitreal Injections | Humans | Vascular Endothelial Growth Factor A - blood | Half-Life | Biological Availability | Male | Angiogenesis Inhibitors - pharmacokinetics | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Tissue Distribution | Vitreous Body - metabolism | Wet Macular Degeneration - metabolism | Antibodies, Monoclonal, Humanized - pharmacokinetics | Receptors, Vascular Endothelial Growth Factor - pharmacokinetics | Recombinant Fusion Proteins - pharmacokinetics | Ranibizumab | Female | Aged | Research | Pharmacokinetics | Vascular endothelial growth factor | Analysis | Macular degeneration | Studies | Oncology | Diabetes | Drug dosages | Molecular weight | Index Medicus | Retina | 1506 | Clinical Science
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
by Avery, Robert L and Pieramici, Dante J and Rabena, Melvin D and Castellarin, Alessandro A and Nasir, Ma’an A and Giust, Matthew J
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2006, Volume 113, Issue 3, pp. 363 - 372.e5
Biological and medical sciences | Miscellaneous | Medical sciences | Ophthalmology | Retina - drug effects | Choroidal Neovascularization - diagnosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Choroidal Neovascularization - etiology | Male | Retinal Detachment - drug therapy | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Bevacizumab | Antibodies, Monoclonal, Humanized | Choroidal Neovascularization - drug therapy | Retinal Detachment - diagnosis | Aged, 80 and over | Vitreous Body | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Fluorescein Angiography | Macular Degeneration - physiopathology | Tomography, Optical Coherence | Fovea Centralis | Macular Degeneration - complications | Vascular Endothelial Growth Factor A - immunology | Visual Acuity | Choroidal Neovascularization - physiopathology | Pigment Epithelium of Eye | Injections | Antibodies, Monoclonal - administration & dosage | Papilledema - diagnosis | Aged | Retina - pathology | Papilledema - drug therapy | Macular degeneration | Physiological aspects | Eye diseases | Angiogenesis inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions
by Pieramici, Dante J., MD and Rabena, Melvin, BS and Castellarin, Alessandro A., MD and Nasir, Ma'an, MD and See, Robert, MD and Norton, Tamara, MPH and Sanchez, Andres and Risard, Sarah and Avery, Robert L., MD
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2008, Volume 115, Issue 10, pp. e47 - e54
Ophthalmology | Prospective Studies | Retinal Vein Occlusion - diagnosis | Tomography, Optical Coherence | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Visual Acuity | Retinal Vein Occlusion - complications | Antibodies, Monoclonal, Humanized | Macular Edema - etiology | Injections | Pilot Projects | Antibodies, Monoclonal - administration & dosage | Macular Edema - diagnosis | Macular Edema - drug therapy | Ranibizumab | Aged, 80 and over | Vitreous Body | Adult | Female | Aged | Fluorescein Angiography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial
by Bressler, Susan B and Odia, Isoken and Maguire, Maureen G and Dhoot, Dilsher S and Glassman, Adam R and Jampol, Lee M and Marcus, Dennis M and Solomon, Sharon D and Sun, Jennifer K and Diabetic Retinopathy Clinical Res and Diabetic Retinopathy Clinical Research Network and for the Diabetic Retinopathy Clinical Research Network
JAMA ophthalmology, ISSN 2168-6165, 01/2019, Volume 137, Issue 4, pp. 382 - 389
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Diabetic Retinopathy - drug therapy | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Humans | Macular Edema - pathology | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Ranibizumab - therapeutic use | Diabetic Retinopathy - pathology | Diabetic Retinopathy - physiopathology | Macular Edema - physiopathology | Macular Edema - drug therapy | Angiogenesis Inhibitors - therapeutic use | Female | Aged | Visual Acuity - physiology | Macula Lutea - pathology | Edema | Diabetic retinopathy | Retinopathy | Diabetes mellitus | Clinical trials | Patients | Acuity | Bevacizumab | Eye | Vision | Hemoglobin | Diabetes | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus | Online First | Original Investigation | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab
by Avery, Robert L and Castellarin, Alessandro A and Steinle, Nathan C and Dhoot, Dilsher S and Pieramici, Dante J and See, Robert and Couvillion, Stephen and Nasir, Ma'An A and Rabena, Melvin D and Maia, Mauricio and Van Everen, Sherri and Le, Kha and Hanley, William D
Retina (Philadelphia, Pa.), ISSN 0275-004X, 10/2017, Volume 37, Issue 10, pp. 1847 - 1858
anti-VEGF | pharmacokinetics | retinal vein occlusion | age-related macular degeneration | diabetic macular edema | Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Diabetic Retinopathy - drug therapy | Prospective Studies | Follow-Up Studies | Intravitreal Injections | Ranibizumab - pharmacokinetics | Humans | Middle Aged | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Angiogenesis Inhibitors - administration & dosage | Female | Recombinant Fusion Proteins - administration & dosage | Bevacizumab - administration & dosage | Enzyme-Linked Immunosorbent Assay | Vascular Endothelial Growth Factor A - blood | Bevacizumab - pharmacokinetics | Angiogenesis Inhibitors - pharmacokinetics | Macular Edema - blood | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Wet Macular Degeneration - diagnosis | Diabetic Retinopathy - blood | Wet Macular Degeneration - drug therapy | Recombinant Fusion Proteins - pharmacokinetics | Macular Edema - drug therapy | Wet Macular Degeneration - blood | Ranibizumab - administration & dosage | Aged | Drug therapy | Retinal diseases | Index Medicus | Original Study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
by Avery, Robert L and Pearlman, Joel and Pieramici, Dante J and Rabena, Melvin D and Castellarin, Alessandro A and Nasir, Ma’an A and Giust, Matthew J and Wendel, Robert and Patel, Arun
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2006, Volume 113, Issue 10, pp. 1695 - 1705.e6
Miscellaneous | Diabetes. Impaired glucose tolerance | Retinopathies | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Ophthalmology | Endocrine pancreas. Apud cells (diseases) | Diabetic Retinopathy - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Diabetic Retinopathy - diagnosis | Angiogenesis Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Vitreous Body | Adult | Female | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Fluorescein Angiography | Iris - blood supply | Retinal Neovascularization - diagnosis | Neovascularization, Pathologic - diagnosis | Tomography, Optical Coherence | Vascular Endothelial Growth Factor A - immunology | Visual Acuity | Injections | Antibodies, Monoclonal - administration & dosage | Neovascularization, Pathologic - drug therapy | Aged | Retinal Neovascularization - drug therapy | Diabetic retinopathy | Care and treatment | Angiogenesis inhibitors | Neovascularization | Consulting services | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion
by Rabena, Melvin D and Pieramici, Dante J and Castellarin, Alessandro A and Nasir, Ma'an A and Avery, Robert L
Retina (Philadelphia, Pa.), ISSN 0275-004X, 04/2007, Volume 27, Issue 4, pp. 419 - 425
Intravitreal | Macular edema | Branch retinal vein occlusion | Avastin | Bevacizumab | Tomography, Optical Coherence | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Visual Acuity | Retinal Vein Occlusion - complications | Antibodies, Monoclonal, Humanized | Macular Edema - etiology | Injections | Retinal Vein Occlusion - drug therapy | Macular Edema - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Vitreous Body | Adult | Female | Aged | Retrospective Studies | Fluorescein Angiography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration Results from the Prospective Proxima A and B Clinical Trials
by Holekamp, Nancy and Wykoff, Charles C and Schmitz-Valckenberg, Steffen and Mones, Jordi and Souied, Eric H and Lin, Hugh and Rabena, Melvin D and Cantrell, Ronald A and Henry, Erin C and Tang, Fan and Swaminathan, Balakumar and Martin, Jillian and Ferrara, Daniela and Staurenghi, Giovanni
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 06/2020, Volume 127, Issue 6, pp. 769 - 783
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Choroidal Neovascularization - diagnosis | Prospective Studies | Follow-Up Studies | Geographic Atrophy - diagnosis | Humans | Middle Aged | Geographic Atrophy - drug therapy | Geographic Atrophy - physiopathology | Male | Immunoglobulin Fab Fragments - therapeutic use | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Vision Disorders - physiopathology | Choroidal Neovascularization - drug therapy | Aged, 80 and over | Female | Visual Acuity - physiology | Fluorescein Angiography | Macular Degeneration - physiopathology | Macular Degeneration - complications | Geographic Atrophy - etiology | Choroidal Neovascularization - physiopathology | Disease Progression | Aged | Choroidal Neovascularization - complications | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration
by Holekamp, Nancy and Wykoff, Charles C and Schmitz-Valckenberg, Steffen and Monés, Jordi and Souied, Eric H and Lin, Hugh and Rabena, Melvin D and Cantrell, Ronald A and Henry, Erin C and Tang, Fan and Swaminathan, Balakumar and Martin, Jillian and Ferrara, Daniela and Staurenghi, Giovanni
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 06/2020, Volume 127, Issue 6, pp. 769 - 783
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials
by Willoughby, Alex S., BS and Ying, Gui-shuang, PhD and Toth, Cynthia A., MD and Maguire, Maureen G., PhD and Burns, Russell E., AAS and Grunwald, Juan E., MD and Daniel, Ebenezer, MBBS, MD and Jaffe, Glenn J., MD and Comparison of Age-Related Macular Degeneration Treatments Trials Research Group and Comparison Age-Related Macular
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2015, Volume 122, Issue 9, pp. 1846 - 1853.e5
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Geographic Atrophy - physiopathology | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Retinal Pigment Epithelium | Wet Macular Degeneration - drug therapy | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Retina - pathology | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
by Altaweel, Michael M., MD and Daniel, Ebenezer, MBBS, PhD and Martin, Daniel F., MD and Mittra, Robert A., MD and Grunwald, Juan E., MD and Lai, Michael M., MD, PhD and Melamud, Alexander, MD, MA and Morse, Lawrence S., MD, PhD and Huang, Jiayan, MS and Ferris, Frederick L., MD and Fine, Stuart L., MD and Maguire, Maureen G., PhD and Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group and Comparison Age-related Macular and Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2015, Volume 122, Issue 2, pp. 391 - 398.e5
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Choroidal Neovascularization - diagnosis | Prospective Studies | Follow-Up Studies | Intravitreal Injections | Humans | Male | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Retinal Hemorrhage - diagnosis | Antibodies, Monoclonal, Humanized - administration & dosage | Choroidal Neovascularization - drug therapy | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Retinal Hemorrhage - physiopathology | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Treatment Outcome | Choroidal Neovascularization - physiopathology | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Aged | Retinal Hemorrhage - drug therapy | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Demarcation laser photocoagulation induced retinal necrosis and rupture resulting in large retinal tear formation
by Quezada, Carlos, MD and Pieramici, Dante J and Matsui, Rodrigo and Rabena, Melvin and Graue, Federico
Photodiagnosis and photodynamic therapy, ISSN 1572-1000, 2015, Volume 12, Issue 2, pp. 314 - 316
Hematology, Oncology and Palliative Medicine | Internal Medicine | Photocoagulation | Retinal detachment | Retinal tear | Laser | Life Sciences & Biomedicine | Oncology | Science & Technology | Retinal Detachment - etiology | Female | Retinal Perforations - etiology | Light Coagulation - adverse effects | Humans | Middle Aged | Laser coagulation |